The company says its automated scan takes roughly two minutes per breast, compared with up to 45 minutes for a conventional handheld ultrasound, and produces a repeatable view that handheld scans, which depend on whoever holds the probe, typically cannot match from one year to the next. ATUSA is commercially available through partner clinics in California, Texas, Georgia, Tennessee and Washington D.C., and a multicentre clinical study with 3,200 patients is underway to validate the platform further.

Elsewhere in the screening pipeline, Whiterabbit.ai offers FDA-cleared software called WRDensity that automatically assesses breast density from mammograms, plus a decision support tool for estimating long-term breast cancer risk. The company is also researching AI that could help radiologists detect more cancers while automatically clearing mammograms that show no sign of the disease, with the stated aim of reducing callbacks and easing pressure on a strained radiologist workforce.

After diagnosis, Ataraxis AI is working on models that analyse digital pathology slides, already part of the standard workup, to predict recurrence risk and how a cancer is likely to respond to treatment. That could shorten a process that today often requires a separate tissue biopsy and a two- to four-week wait for genomic assay results from outside labs.